Cantor Fitzgerald Cuts Zevra Therapeutics Price Target to $19 From $25
Cantor Fitzgerald lowered its Zevra Therapeutics price target to $19 from $25 while keeping an Overweight rating, according to Dow Jones Newswires citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Analysts at Cantor Fitzgerald reduced their price target on Zevra Therapeutics shares to $19 from $25, Dow Jones Newswires reported, citing Benzinga ratings data. The firm kept its Overweight rating on the stock, meaning it still sees the shares as a relative buy.
why it matters
A price target change reflects one analyst's view of a single company and rarely shifts the broader market. Biotech investors still track such moves as a gauge of sentiment toward individual names.
tags
instruments
sources
- Zevra Therapeutics Price Target Cut to $19.00/Share From $25.00 by Cantor Fitzgerald — Dow Jones Newswires, 13 November 2026 at 18:22 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗